Michael Linnebank: Fampridin zur Verbesserung der Gehfähigkeit. In: Forte. Nr.4, November 2012, ZDB-ID 2412672-X (multiplesklerose.ch [PDF]).
neurology.org
Richard Macdonnell, Guy Nagels, Per Solberg Sorensen, David Laplaud, Carlo Pozzilli, Ana Silva, Richard Nicholas, Mathias Niedhammer, Julia Gaebler, Sonalee Agarwal and James Potts: Change in Quality of Life Outcomes with Prolonged-Release Fampridine Treatment: Interim Analysis of the ENABLE Study. In: Neurology. Band80, Supp. 7, 2013, S.P03.218–P03.218 (neurology.org).
nih.gov
ncbi.nlm.nih.gov
T. Pickett, R. Enns: Atypical presentation of 4-aminopyridine overdose. In: Ann Emer Med. 27, 1996, S. 382–385. PMID 8599505.
N. Johnson, M. Morgan: An unusual case of 4-aminopyridine toxicity. In: J Emer Med. 30, 2006, S. 175–177. PMID 16567254.
A. D. Goodman, T. R. Brown, L. B. Krupp u. a.: Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. In: The Lancet. 373, 2009, S. 732–738. PMID 19249634.
A. D. Goodman, T. R. Brown, K. R. Edwards u. a.: A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. In: Ann Neurol. 68, 2010, S. 494–502. PMID 20976768.
Raymond Lamore III, Elsen Jacob, Susan C. Jacob, Olga Hilas: Dalfampridine (Ampyra). In: Pharmacy and Therapeutics. Band35, Nr.12, 2010, S.665–669, PMC 3008376 (freier Volltext).
Recommended International Nonproprietary Names for Pharmaceutical Substances. INN List 35. In: WHO Drug Information. Band9, Nr.3, 1995, S.174 (who.int [PDF]).
zdb-katalog.de
Michael Linnebank: Fampridin zur Verbesserung der Gehfähigkeit. In: Forte. Nr.4, November 2012, ZDB-ID 2412672-X (multiplesklerose.ch [PDF]).